mortality/aging
• after injection of platelet-activating factor (PAF), less than 10% mortality occurs within 30 minutes
• pretreatment with wortmannin before PAF treatment confers 100% protection to mutants and wild-type
• in BSA-induced anaphylaxis, all mutants survive compared to fatality in 82% of controls; in OVA model, 92% of control mice die but all mutants survive challenge
|
growth/size/body
• body weights at 14 weeks of age are approximately 7.5% lower than in wild-type
(J:36559)
• body weight is signifcantly lower than controls at 14 days of age
(J:101254)
|
homeostasis/metabolism
• plasma renin concentrations are nearly twice as high as in wild-type
|
• challenge with BSA 2 weeks after sensitization with BSA induces severe hypothermia and mice succumb to systemic shock reaction; mutants show no mortality and only a delayed, mild, transient hypothermia
• similar results are seen with OVA-induced anaphylaxis
|
cardiovascular system
• larger than in controls but only at 14 day
• medial wall area is greater than in controls in the fetus
• muscularity decreases after birth
• muscularity is reduced in the male but still greater than controls
• muscularity in females is like controls by 14 days of age
|
• right ventricle/body weight ratio increased in males
• right ventricle/left ventricle+septum ratio increased in males
|
• mean right ventricular pressure is elevated in males but not in females
|
• 670 beats per min vs. 709 beats per min in wild-type
|
• elevated in males but not in females
|
• in BSA/BSA model of anaphylaxis, vascular permeability increased significantly in wild-type but very little in mutants; vascular leakage (extravasation) of Evans Blue dye (EB) is 2-fold lower than in wild-type mice
• in OVA/OVA model, no vascular permeability increase occurs in mutants and extravasation is significantly lower than in wild-type
|
immune system
N |
• exhibit a similar susceptibility to lipopolysaccharide-induced death as wild-type
|